Previous 10 | Next 10 |
Kamada (NASDAQ:KMDA) announced the acquisition of four FDA-approved plasma-derived hyperimmune products from Saol Therapeutics for an upfront payment of $95M. Per the terms, Saol is also entitled to receive up to $50M based on sales milestones during 2022-2034. In addition, Kamada (KMDA)...
2021 Global Revenue of the Portfolio Acquired from Saol Therapeutics is Estimated Between $40 Million to $45 Million , with Approximately 75% and 20% of Sales Generated from U.S. and Canada, Respectively Acquisition Advances Kamada...
Kamada (NASDAQ:KMDA): Q3 GAAP EPS of -$0.02 misses by $0.05. Revenue of $23.03M (-34.8% Y/Y) misses by $2.17M. Press Release For further details see: Kamada EPS misses by $0.05, misses on revenue
Third Quarter 202 1 Revenues were $ 23.0 Million and Total R evenues for the First Nine Months of 2021 were $72.2 M illion Kamada has Acqui red a Portfolio of Four FDA-Approved Plasma-Derived Hyperimmune...
Kamada (NASDAQ:KMDA) is scheduled to announce Q3 earnings results on Monday, November 22nd, before market open. The consensus EPS Estimate is $0.02 (-86.7% Y/Y) and the consensus Revenue Estimate is $25.2M (-28.7% Y/Y). Over the last 3 months, EPS estimates have seen 0 upward revisions and 1 ...
AVYA, CRNC, KMDA, NIU, TWST For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings before Monday's open
REHOVOT, Israel, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived biopharmaceutical company, today announced that it will release financial results for the three and nine months ended September 30, 2021, prior to the open of the U.S. financial market...
The pharmaceutical industry’s increased focus on developing better treatments for many of today's most complex diseases should help it to grow for the foreseeable future. However, because highly priced pharma stocks are susceptible to anticipated market volatility in the near term, we ...
The pharmaceutical industry is expected to attract significant investor attention in the coming months as the demand for vaccines and therapies continues to soar with the resurgence of COVID-19 cases globally. This demand, coupled with an astonishing level of scientific advances for treating ...
Kamada Limited (KMDA) Q2 2021 Earnings Conference Call August 11, 2021 08:30 ET Company Participants Bob Yedid - LifeSci Advisors Amir London - Chief Executive Officer Chaime Orlev - Chief Financial Officer Conference Call Participants Anthony Petrone - Jefferies Presentation Operator Greetin...
News, Short Squeeze, Breakout and More Instantly...
2024-07-17 17:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-17 04:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...